2021
Face Perception Predicts Affective Theory of Mind in Autism Spectrum Disorder but Not Schizophrenia or Typical Development
Altschuler MR, Trevisan DA, Wolf JM, Naples AJ, Foss-Feig JH, Srihari VH, McPartland JC. Face Perception Predicts Affective Theory of Mind in Autism Spectrum Disorder but Not Schizophrenia or Typical Development. Journal Of Psychopathology And Clinical Science 2021, 130: 413-422. PMID: 34180705, PMCID: PMC8244155, DOI: 10.1037/abn0000621.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderBenton Facial Recognition TestSchizophrenia spectrum disordersAffective ToM abilitiesTypical developmentSpectrum disorderAffective ToMToM difficultiesSocial cognitionToM abilitiesIndividual differencesBetter face recognition abilityFace recognition abilityFace recognition difficultiesTheory of mindFacial Recognition TestFull Scale IQFace perceptionAffective theoryRecognition difficultiesRecognition testEyes TestSocial dysfunctionRecognition abilityFace recognition
2019
Early intervention service for first episode psychosis in Modena, Northern Italy: The first hundred cases
Ferrara M, Tedeschini E, Baccari F, Musella V, Vacca F, Mazzi F, Ferri M, Srihari V, Starace F, Group F. Early intervention service for first episode psychosis in Modena, Northern Italy: The first hundred cases. Early Intervention In Psychiatry 2019, 13: 1011-1017. PMID: 30672134, DOI: 10.1111/eip.12788.Peer-Reviewed Original ResearchConceptsEarly intervention servicesClinical improvementMedian ageIntervention servicesCommunity mental health centerCommunity outpatient servicesPsychiatric hospital unitMeaningful clinical improvementFirst-episode psychosisModel of careNon-affective psychosisNation Outcome ScalesMental health centersHigher median ageEarly detection effortsRefinement of treatmentMain referralsPharmacological consultationYounger patientsUntreated psychosisOutcome ScaleGeneral practitionersEpisode psychosisHealth centersOutpatient services
2018
Course, outcome and diagnosis stability of early-onset schizophrenia in Yunnan Province, China-a three years follow-up study
Kang C, Zhou H, Yang J, Yang R, Sun N, Wang S, Yang C, Han D, Srihari VH. Course, outcome and diagnosis stability of early-onset schizophrenia in Yunnan Province, China-a three years follow-up study. Psychiatry Research 2018, 271: 144-149. PMID: 30472510, DOI: 10.1016/j.psychres.2018.11.013.Peer-Reviewed Original ResearchConceptsEarly-onset schizophreniaICD-10 diagnosisDiagnostic stabilityMini International Neuropsychiatric InterviewFirst Affiliated HospitalInternational Neuropsychiatric InterviewKunming Medical UniversityHigh diagnostic stabilityDepartment of PsychiatryPoor outcomeAffiliated HospitalNeuropsychiatric InterviewInternational ClassificationBetter outcomesModerate outcomeMedical UniversityGlobal functioningICD-10Psychosocial outcomesPatientsSchizophreniaDiagnosis stabilityDiagnosisOutcomesHospital
2015
First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial
Srihari VH, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJ, Pollard J, Ozkan B, Saksa J, Walsh BC, Woods SW. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. Psychiatric Services 2015, 66: 705-712. PMID: 25639994, PMCID: PMC4490067, DOI: 10.1176/appi.ps.201400236.Peer-Reviewed Original ResearchConceptsUsual treatmentSTEP participantsCommunity mental health centerFirst-episode servicesFirst-episode psychosisMental health centersSerious mental illnessInpatient psychiatric unitAntipsychotic exposureAdditional patientsIllness onsetHospital utilizationHealth centersInpatient utilizationPsychiatric hospitalizationMAIN OUTCOMEPsychotic illnessPsychiatric unitPsychotic disordersHospitalizationEarly interventionMental illnessSpecialized treatmentPatientsTranslational research
2014
The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial
Tek C, Palmese LB, Krystal AD, Srihari VH, DeGeorge PC, Reutenauer EL, Guloksuz S. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research 2014, 160: 180-185. PMID: 25454802, PMCID: PMC5589464, DOI: 10.1016/j.schres.2014.10.002.Peer-Reviewed Original ResearchMeSH KeywordsAzabicyclo CompoundsCognitionDouble-Blind MethodEszopicloneFemaleHumansHypnotics and SedativesMaleMedical RecordsMiddle AgedPatient DropoutsPiperazinesPsychotic DisordersQuality of LifeSchizophreniaSchizophrenic PsychologySingle-Blind MethodSleepSleep Initiation and Maintenance DisordersTreatment OutcomeConceptsInsomnia Severity IndexSingle-blind placebo phasePlacebo phaseOutcome measuresPsychiatric symptomsPlacebo-controlled trialDouble-blind placeboSecondary outcome measuresPrimary outcome measureEffects of eszopicloneBetween-group differencesTreatment of insomniaQuality of lifeDiscontinuation ratesMATRICS Consensus Cognitive BatteryStable outpatientsConsensus Cognitive BatterySchizoaffective disorderCognitive impairmentSleep diaryPatientsInsomniaScore changeEszopiclonePlacebo
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight lossCardiovascular mortality in schizophrenia: Defining a critical period for prevention
Srihari VH, Phutane VH, Ozkan B, Chwastiak L, Ratliff JC, Woods SW, Tek C. Cardiovascular mortality in schizophrenia: Defining a critical period for prevention. Schizophrenia Research 2013, 146: 64-68. PMID: 23422728, PMCID: PMC3622848, DOI: 10.1016/j.schres.2013.01.014.Peer-Reviewed Original ResearchConceptsPremature cardiovascular mortalityCardiovascular mortalityCardiovascular riskUrban community mental health centerCommunity mental health centerCardiovascular risk estimatesPrior antipsychotic exposureRace-matched peersCardiovascular risk factorsEarly psychosis clinicMental health centersSuch preventive effortsLow-risk categoryCritical periodAntipsychotic exposureBlood pressureMetabolic syndromeObese categoryPsychosis clinicNormal weightPrimary preventionRisk factorsNational HealthHealth centersNutrition Survey
2012
Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness
Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness. Journal Of The Academy Of Consultation-Liaison Psychiatry 2012, 54: 67-73. PMID: 22664309, PMCID: PMC3435456, DOI: 10.1016/j.psym.2012.03.001.Peer-Reviewed Original ResearchConceptsSevere mental illnessGeneral CVD riskSchizophrenia spectrum patientsVascular ageCVD riskSpectrum patientsNHANES participantsMetabolic riskMental illnessGeneral cardiovascular riskMean vascular ageSystolic blood pressureCardiovascular disease mortalityPrimary care cliniciansHDL cholesterol levelsNutrition Examination SurveyCVD eventsCardiovascular riskObese controlsObese patientsBlood pressureCare cliniciansHypertension treatmentSmoking statusExamination SurveyError Monitoring Dysfunction Across the Illness Course of Schizophrenia
Perez VB, Ford JM, Roach BJ, Woods SW, McGlashan TH, Srihari VH, Loewy RL, Vinogradov S, Mathalon DH. Error Monitoring Dysfunction Across the Illness Course of Schizophrenia. Journal Of Psychopathology And Clinical Science 2012, 121: 372-387. PMID: 22060947, PMCID: PMC3358508, DOI: 10.1037/a0025487.Peer-Reviewed Original ResearchConceptsEarly illness schizophrenia patientsClinical high-risk patientsSchizophrenia patientsIllness courseAge-matched healthy controlsHigh-risk patientsAge-matched HCChronic schizophrenia patientsOnset of psychosisCorrect response negativityPE abnormalitiesRisk patientsCHR patientsClinical prodromeEvent-related potentialsIllness durationHealthy controlsIllness progressionPsychosis onsetPatientsAbnormalitiesIllnessResponse monitoringError-related negativityOnset
2011
Insomnia is frequent in schizophrenia and associated with night eating and obesity
Palmese LB, DeGeorge PC, Ratliff JC, Srihari VH, Wexler BE, Krystal AD, Tek C. Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophrenia Research 2011, 133: 238-243. PMID: 21856129, PMCID: PMC5581545, DOI: 10.1016/j.schres.2011.07.030.Peer-Reviewed Original ResearchConceptsBody mass indexQuality of lifeSleep difficultiesMass indexClinical insomniaSevere insomniaNight eatingPoor sleepPsychiatric symptomsTypes of antipsychoticsPrevalence of insomniaRelationship of sleepProminent clinical concernBrief cognitive assessmentIndependent predictorsPoint prevalenceClinical variablesClinical careSleep patternsSchizoaffective disorderClinical concernInsomniaLow qualityWeight gainSchizophrenia
2008
Pulmonary embolism in a patient taking clozapine
Srihari VH, Lee TW. Pulmonary embolism in a patient taking clozapine. The BMJ 2008, 336: 1499. PMID: 18583682, PMCID: PMC2440902, DOI: 10.1136/bmj.39545.690613.47.Peer-Reviewed Original Research
2007
Resolution of Tardive Dyskinesia After Addition of Aripiprazole to Haloperidol Depot
Kantrowitz JT, Srihari VH, Tek C. Resolution of Tardive Dyskinesia After Addition of Aripiprazole to Haloperidol Depot. Journal Of Clinical Psychopharmacology 2007, 27: 525-526. PMID: 17873695, DOI: 10.1097/jcp.0b013e31814f3002.Peer-Reviewed Original ResearchBest Practices: Surveillance and Management of Diabetes in a CMHC Population
Srihari VH, Tek C, Chwastiak LA, Woods SW, Steiner JL. Best Practices: Surveillance and Management of Diabetes in a CMHC Population. Psychiatric Services 2007, 58: 1151-1153. PMID: 17766557, DOI: 10.1176/ps.2007.58.9.1151.Peer-Reviewed Original ResearchConceptsManagement of diabetesType 2 diabetes mellitusCommunity mental health centerMaintenance antipsychotic medicationPercent of patientsCross-sectional studyMental health centersSerious mental illnessCardiovascular profileDiabetes mellitusGlucose dysregulationAntipsychotic medicationCardiovascular healthHealth centersTobacco useGeneral populationUndiagnosed diseaseDiabetesMental illnessPatientsHigh rateHalf timesMellitusMedicationsObesity
2006
Three cases of risperidone-induced enuresis
Kantrowitz JT, Srihari VH, Tek C. Three cases of risperidone-induced enuresis. Schizophrenia Research 2006, 84: 174-175. PMID: 16564679, DOI: 10.1016/j.schres.2006.01.023.Peer-Reviewed Original Research